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Abstract
Background: Glucose-6-phospate dehydrogenase (G6PD) is the limiting enzyme of the pentose phosphate
pathway (PPP) correlated to cancer progression and drug resistance. We previously showed that G6PD inhibition
leads to Endoplasmic Reticulum (ER) stress often associated to autophagy deregulation. The latter can be induced
by target-based agents such as Lapatinib, an anti-HER2 tyrosine kinase inhibitor (TKI) largely used in breast cancer
treatment.
Methods: Here we investigate whether G6PD inhibition causes autophagy alteration, which can potentiate
Lapatinib effect on cancer cells. Immunofluorescence and flow cytometry for LC3B and lysosomes tracker were
used to study autophagy in cells treated with lapatinib and/or G6PD inhibitors (polydatin). Immunoblots for LC3B
and p62 were performed to confirm autophagy flux analyses together with puncta and colocalization studies. We
generated a cell line overexpressing G6PD and performed synergism studies on cell growth inhibition induced by
Lapatinib and Polydatin using the median effect by Chou-Talay. Synergism studies were additionally validated with
apoptosis analysis by annexin V/PI staining in the presence or absence of autophagy blockers.
Results: We found that the inhibition of G6PD induced endoplasmic reticulum stress, which was responsible for
the deregulation of autophagy flux. Indeed, G6PD blockade caused a consistent increase of autophagosomes
formation independently from mTOR status. Cells engineered to overexpress G6PD became resilient to autophagy
and resistant to lapatinib. On the other hand, G6PD inhibition synergistically increased lapatinib-induced cytotoxic
effect on cancer cells, while autophagy blockade abolished this effect. Finally, in silico studies showed a significant
correlation between G6PD expression and tumour relapse/resistance in patients.
Conclusions: These results point out that autophagy and PPP are crucial players in TKI resistance, and highlight a
peculiar vulnerability of breast cancer cells, where impairment of metabolic pathways and autophagy could be
used to reinforce TKI efficacy in cancer treatment.
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Background
In recent years, metabolic deregulations have been stud-
ied as prognostic factors for tumours and as potential
targets for innovative treatments [1–4]. Pentose phos-
phate pathway (PPP), a cytoplasmic metabolic process
parallel to glycolysis, synthesizes the nucleotide precur-
sor ribose-5-phosphate and produces NADPH, the
reduced form of NADP+ (the nicotinamide adenine
dinucleotide phosphate), that is an essential cofactor for
the synthesis of lipids and maintenance of redox balance
of the cell [5, 6]. NADPH counteracts oxidative stress
produced in highly metabolizing cancer cells in form of
reactive oxygen species (ROS). Glucose-6-phosphate
dehydrogenase (G6PD) is the key enzyme of the PPP, it
is often over-expressed in several types of cancer such as
breast cancer, oesophageal carcinoma, renal cancer and
is correlated to worse prognosis [7–10]. Indeed, some of
the main oncogenes and tumour suppressors such as
p53 and K-Ras, can directly regulate the enzymes in-
volved in this pathway [6, 11, 12]. Several studies showed
that the inhibition of G6PD may result in the develop-
ment of therapeutic strategies against tumour growth
and metastasis [13–15].
Breast cancer is the most common type of cancer in
women and is associated with high mortality that is due to
tumour aggressiveness and drug resistance. This cancer is
classified according to the expression of oestrogen recep-
tor (ERec), progesterone receptor (PR), and/or human epi-
dermal growth factor receptor 2 (HER-2). The expression
of these receptors determines the phenotype of the breast
cancer and thus defines the therapeutic strategy to follow
[16, 17]. Lapatinib, an orally administered small-molecule,
is a dual tyrosine kinase inhibitor (TKI) that targets both
HER-2 receptor and the epidermal growth factor receptor
(EGFR), and which has been widely used for the treatment
of breast cancer [18]. This inhibitor induces apoptosis and
autophagy in cancer cells. However, resistance to lapatinib
treatment is also observed. The resistance can be caused
by alterations in autophagosome and autolysosome pro-
teins, suggesting a potential role of autophagy [19–21].
Furthermore, the increase of the antioxidant metabolic
pathway has been associated with TKI resistance in can-
cer. This suggests that the strategies based on the target-
ing of antioxidant metabolic pathways may improve the
efficiency of TKI-based therapy [22]. In this study, we
investigated the interplay between G6PD, ER stress and
autophagy, and highlighted new possible strategies to
improve the effect of TKIs in treatment of breast cancer
overcoming drug resistance.
Materials and methods
Chemicals, cell culture and in vitro treatment
All chemicals were purchased from Sigma-Aldrich (St.
Louis, USA) unless otherwise specified. Trans-polydatin,
with a purity grade higher than 99%, was been supplied
by Ghimas spa (Casalecchio, Bologna, Italy). Selective
inhibitors of IRE1α (4μ8C) and PERK (GSK 2606414)
were obtained from Tocris Bioscience (Bristol, United
Kingdom). Lapatinib (Tyverb®) was obtained from GSK
(Verona, Italy). MCF7 cells were purchased from ATCC.
Cells were cultured in DMEM (Gibco, NY, USA) supple-
mented with 2 mM glutamine, 100 IU/mL penicillin,
100 μg/mL streptomycin (Invitrogen, Carlsbad, CA), and
10% heat-inactivated foetal bovine serum (FBS) (Gibco,
NY, USA) at 37 °C in a humidified atmosphere under 5%
CO2. All cell lines were kept mycoplasma free, checking
was performed every three months.
Cell viability assay
Cell viability was measured by the colorimetric 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Cells were seeded in 96-well plates at a
density of 104 cells per well, then they were treated
with 100 μL of 1mg/mL MTT (Sigma) in DMEM medium
containing 10% foetal bovine serum for 4 h at 37 °C. The
medium was then replaced with 200 μL of DMSO and
shaken for 15min, then absorbance at 540 nm was mea-
sured using a microplate ELISA reader with DMSO used as
the blank. To quantify the synergistic or antagonist effect of
the drugs combinations, CompuSyn software was used [23].
Immunofluorescence staining
After 24 h treatment with PD at various concentrations
or 30 μM chloroquine (autophagy positive control), cells
were washed in PBS and fixed with 4% paraformalde-
hyde (PFA) solution and permeabilized with 0.1% TRI-
TON -X/PBS solution, then was performed a blocking in
1% BSA for 1 hat RT. Cells were incubated with LC3B
antibody (Cell Signalling, USA) and Anti-SQSTM1/p62
(ab56416, Abcam, Cambridge, UK) in PBS for 30 min.
Secondary antibodies were added after a PBS wash in
the same conditions. Cells were incubated in a 1:500
solution of 10 mg/mL Hoechst (Invitrogen) in PBS for
10 min in the dark. To stain endoplasmic reticulum cells
were incubated with 200 nM ER-Tracker Blue-White
DPX in PBS solution for 20 min at 37 °C. For positive
control cells were exposed for 16 h to 5 μg/mL tunica-
mycin. Images were collected under a fluorescence
microscope (EVOS FL Cell Imaging System, Thermo
Scientific, Rockford, USA). To stain lysosomes, cells
were incubated with 60 nM LysoTracker (Thermo Fisher
Scientific, USA) for 45 min at 37 °C. ImageJ (Fiji plugin)
software was used for the calculation of Puncta and In-
tensity correlation quotient (ICQ).
FACS analysis
For intracellular staining cells were fixed with Fix and Perm
Reagent A (Invitrogen) for 20min, and then resuspended
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in Fix and Perm Reagent B (Invitrogen) for 30min contain-
ing primary LC3B antibody (Cell Signalling, USA).
Secondary antibodies were added in Fix and Perm
Reagent B (Invitrogen) in the same conditions. Apop-
tosis (Annexin V apoptosis detection kit, BD biosci-
ences), CellROX assay (Thermo Fisher Scientific, USA),
LysoTracker assay (Thermo Fisher Scientific, USA), were
performed according to the manufacturer’s instructions.
Cells were analyzed with a FACSAria III (BD Biosciences,
San Jose, CA) or a BD Accuri Cytometer (BD Biosciences,
San Jose, CA). Data were analysed by FlowJo V10 software
(FlowJo LLC, USA).
G6PD overexpression
p3-G6PD-t1 and negative control pCMV3-untagged-NCV
(control) hygromycin-resistant plasmids were purchased
from Sino Biological Inc. (Sino Biological, Beijing, China).
MCF7 cells were stably transfected with Lipofectamine 3000
(Thermo Fisher Scientific, Waltham, MA USA) according
to the manufacturer’s instructions. Clones with upregulated
expression of G6PD were selected with 100 μg/mL
Hygromycin. Clones were screened by Western blot.
Protein extraction and Western blotting
Cells were lysed in 1x RIPA buffer (150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM
Tris. Cl pH 7.5) plus 1% protease inhibitor cocktail, 1%
PMSF (200 mM) and 1% sodium orthovanadate (Santa
Cruz Biotechnology, USA). Lysates were clarified by cen-
trifugation at 8000 x g for 5 min at 4 °C and equal
amounts of protein were fractionated by SDS-PAGE and
subsequently transferred onto nitrocellulose membrane,
immunoblots were visualized using Supersignal® West
Pico Chemiluminescent substrate (Thermo Scientific,
Rockford, USA). Proteins were detected with anti-Glucose
6 Phosphate Dehydrogenase (Novus Biologicals, USA);
Anti-SQSTM1 / p62 (ab56416, Abcam, Cambridge, UK);
anti-Phospho-Akt (Ser473) (9271, Cell Signalling, USA),
anti-Akt (9272, Cell Signalling, USA); anti-phospho-mTOR
(Ser2448) (2971, Cell Signalling, USA); anti-mTOR (2972,
Cell Signalling, USA); anti-LC3B (2775, Cell Signalling,
USA); anti-α-Tubulin Antibody (#2144 Cell Signalling
Technology, UK); Anti-GAPDH (ab9485, Abcam,
Cambridge, UK) were used for assessing loading.
In silico analysis
In silico validation was performed using gene expression
profiles generated as part of the Molecular Taxonomy of
Breast Cancer International Consortium (METABRIC)
[24] and Pawitan [25] studies. The gene expression pro-
files were generated using an Illumina HT-12 v3.0 Gene
Expression BeadChip (METABRIC) and an Affymetrix
Human Genome U133A/U133B (Pawitan) array. The
gene expression of G6PD was selected and min-max
normalised across the complete patient population of
both datasets. The normalised gene expression was ana-
lysed using scatter plots for the differentiation of G6PD ex-
pression across breast cancer subtypes (Her2+ enriched,
Basal-like, Luminal A, Luminal B and Normal-like) and dis-
ease recurrence. Unpaired t-test was used to analyse differ-
ences between sample groups. In addition, Kaplan-Meier
curves were generated presenting disease-free survival
(DFS) in relation to G6PD expression. Patient groups were
separated according to median expression and survival
curves were analysed using Mantel-Cox test. P-values
below 0.05 were considered to be significant (p ≤ 0.05 = *,
p ≤ 0.01 = **, p ≤ 0.001 = *** and p ≤ 0.0001 = ****). Analysis
was performed using GraphPad Prism 8.
Results
G6PD inhibition induces autophagy in breast cancer cells
Autophagy is a biological survival mechanism that is ac-
tivated in cells during stress. Activation of this pathway
in cancer cells can favour or hinder cancer progression
depending on cell context. In a previous work [26], we
showed that the natural molecule polydatin directly in-
hibits G6PD by inducing reactive oxygen species (ROS)
and increasing Endoplasmic Reticulum (ER) stress. Both
biological effects are frequently associated with increased
autophagic flux. This led us to investigate the effect of
G6PD blockade on autophagy and its role in breast
cancer cells response to treatment. Macroautophagy
(from now on autophagy) is a cellular process that allow
for orderly degradation recycling of cellular organelles.
The major steps of this process include the formation of
autophagosome, vesicles containing the organelles to be
degraded, and successively the fusion of these with lyso-
some (autophagolysosomes). Autophagosomes formation
involves the recruitment of LC3B (Microtubule-asso-
ciated protein 1A/1B-light chain 3) and p62/sequesto-
some proteins. In order to monitor autophagy in treated
cells, we performed an IF and a quantitative analysis by
flow cytometry using the vital dye LysoTracker, LAMP1
and LC3B antibody. LysoTraker is a fluorescent dye for
labelling and tracking acidic organelles in live cells, thus
it will stain both lysosomes and autophagolysosomes.
Both qualitative and quantitative analyses showed a
consistent increase in autophagy following exposure to
polydatin (Fig. 1a,b). Lysotracker staining showed a
strong increase in acidic vesicles after treatment as
assessed by measuring median fluorescence ranging
from 11,603 (untreated (NT)) to 16,551 (treated with
30 μM Polydatin). LC3B staining indicated the appear-
ance of several fluorescent vesicles with a median fluor-
escence ranging between 41,709 (untreated) to 204,124
(treated with 30 μM Polydatin). To investigate the for-
mation of autophagic vesicles, we analysed the LC3B
puncta per cells (Fig. 1c). Typically, LC3B associated to
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autophagosomes is visualized in immunofluorescence as
dots (puncta), each dot representing an autophagosome.
We found a consistent increase of puncta in a Polydatin
concentration-dependent manner. When is recruited
on autophagosomes LC3B becomes conjugated with
phosphatidylethanolamine (LC3BII) [27]. The activation
of LC3BI (LC3BII) was also confirmed by immunoblot-
ting (Fig. 1d) and band densitometry showed a signifi-
cant increase in LC3BII following increasing Polydatin
concentrations.
To better understand the effect of G6PD blockade on
autophagy (e. g. if it increases or blocks autophagic flux
with accumulation of autophagosomes), we performed
an analysis of autophagic flux by co-treating the cells
with chloroquine, a drug that block the fusion of autopha-
gic vesicles and lysosomes, resulting in the blockade of
autophagic flux and accumulation of autophagosomes.
Thus, when a drug works by blocking the autophagy flux,
its effect on autophagy markers (LC3B and p62) will be re-
duced or abrogated by co-treating with chloroquine; on the
other hand, if a drug increases the autophagic flux its effect
on autophagy markers will be increased. Indeed, cells
treated with chloroquine showed a strong staining of both
LysoTracker and LC3B by IF (Fig. 2 a, b) and increased
protein expression of LC3BII and p62/sequestosome (Fig.
2c). When cells were co-treated with chloroquine and poly-
datin, a significant increase of LysoTracker staining and
expression of LC3BII and p62/sequestosome were also ob-
served (Fig. 2 a, b, c). Moreover, we calculated the Intensity
correlation quotient (ICQ) on the IF using LC3B and Lyso-
Tracker double staining. The ICQ expresses the amount of
co-localization between the two staining, that in this case
ranged between 50 and 60% (ICQ= 0,26-0,32). In all these
experiments the co-treatment with polydatin and chloro-
quine constantly resulted in a stronger signal compared to
single treatments. This suggests that polydatin induced an
increase of autophagic flux.
Autophagy is dependent on ER stress
Autophagy can be induced by different mechanisms
both in physiological and pathological conditions. One
of the key pathways controlling autophagy activation is
represented by the AKT/mTOR. TOR is a central regu-
lator of cell growth and metabolism, and in response to
nutritional and stress signals, it coordinates the balance
between cell growth and autophagy. Polydatin has been
suggested to act as an mTOR inhibitor and inducer of
autophagy [28]. To exclude a potential and direct inhibi-
tory effect of Polydatin on mTOR and to clarify its rela-
tion with G6PD inhibition, we performed immunoblots
for the inactive and active (phosphorylated) forms of
both AKT and mTOR (Fig. 3 a). This experiment does
not show an inhibition of AKT and mTOR, on the con-
trary both AKT and mTOR expression increased while
the ratio between the non-phosphorylated and the phos-
phorylated form did not change after treatments. These
results suggest that the induction of autophagy was not
driven by mTOR inhibition as reported for resveratrol
but follows a different cell mechanism. Indeed, autoph-
agy has been shown to be induced by UPR (Unfolded
Protein Response), as a mechanism of degradation of
misfolded proteins, which activation could be mediated
by IRE1 or PERK [29–32]. In a previous work [26], we
showed that G6PD inhibition induces a strong ER stress
Fig. 1 G6PD inhibition induces autophagy. a Autophagy analysis on
polydatin-treated cells (10–30 μM) performed by immunofluorescence
for LAMP1 (top row) and LC3B protein (lower row), 24 h after treatment.
b Flow cytometry histograms for the Lysotraker and Lc3B, median
fluorescence values are shown in the graphs. Both IF and flow cytometry
show an increase of LAMP1, LysoTracker and LC3B fluorescence
accordingly to polydatin concentration. c Analysis of puncta on IF for
LC3B in polydatin-treated cells (10–30 μM), 24 h after treatment. Puncta
represent single autophagosomes. d Immunoblot for LC3B and p62;
band densitometry in polydatin treated cells (10–30 μM), 24 h after
treatment. LC3BII increases accordingly to polydatin concentration while
p62 decreases. p < 0.05, N = 3 (Biological replicates); error bars = SEM
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with activation of both PERK and IRE1. Here we confirmed
a strong activation of ER stress by ER TRacker staining, this
vital dye stains the endoplasmic reticulum and its fluores-
cence was proportional to ER swelling (Fig. 3b). Inhibition
of PERK or IRE1 phosphorylation by specific inhibitors
reduced autophagy in polydatin-treated cells, suggesting a
causative link between ER stress and autophagy (Fig. 3c).
G6PD overexpression reduces autophagy and induces
resistance to Lapatinib
Lapatinib is an orally active drug for breast cancer ther-
apy. It is a tyrosine kinase inhibitor which acts on both
HER2/neu and epidermal growth factor receptor (EGFR)
[33]. Lapatinib has been shown to induce both apoptosis
and autophagy in cancer cells [19–21, 34]. Based on this,
we hypothesised that G6PD blockade could increase
Lapatinib effect on cancer. On the other hand, G6PD
overexpression is common in several cancers and corre-
lates with aggressiveness and poor prognosis [7, 8, 35].
Thus, we generated a cell line overexpressing G6PD
(MCF7G6PD+) [26] and compared the activation of
autophagy with control cells (mock plasmid MCF7mock)
when treated with both polydatin and lapatinib. Lapati-
nib concentration was chosen from a viability assay per-
formed on MCF7 (Fig. 5 a) to be the minimum effective
concentration. As shown in Fig. 4, lapatinib induced
Fig. 2 Analysis of autophagy flux. a IF with Lysotracker and LC3B for autophagy flux analysis on cells treated with polydatin (10 μM), chloroquine
(30 μM) and their combination. Co-treatment with chloroquine increases the fluorescence of both LysoTracker and LC3B suggesting that
polydatin triggers autophagy. Intensity correlation quotient (ICQ) shows the grade of co-localization of LC3B and Lysotracker; in all three
treatments a colocalization grade of about 70% was recorded. b Analysis of puncta for IF of LC3B and Lysotracker on cells treated with polydatin
(10 μM), chloroquine (30 μM) and their combination. c Immunoblot with band densitometry for LC3B and P62/sequestosome on cells treated
with polydatin (10 μM), chloroquine (30 μM) and their combination. Increase of LC3B and p62 bands in cells co-treated with polydatin and
chloroquine confirms that polydatin triggers autophagic flux. *p < 0.05, N = 3; error bar = 95% confidence
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autophagy in MCF7mock but on much less extend on
MCF7G6PD+ cells as visualized with both lysotracker
(Fig. 4 a) and LC3B (Fig. 4 b) for IF and flow cytometry.
Interestingly, the combination lapatinib/polydatin re-
sulted in increased activation of autophagy. In order to
confirm these data, we performed an immunoblot for
LAMP1, p62 and LC-3. LAMP1 increases with all treat-
ment on MCF7mock confirming an increase in the
lysosomal compartment. On MCF7G6PD+ polydatin didn’t
produce any increase in LAMP1 while lapatinib and
combo did but at much less extend than on MCF7mock.
p62 decreased on MCF7mock with all treatments and espe-
cially with the combo, on MCF7G6PD+ only the combo in-
duces a decrease. LC-3BII/LC-3BI ratio.
To show if the effect on autophagy was reflected on
cell viability, we performed a viability assay and studied
Fig. 3 Autophagy is dependent on ER stress. a Immunoblot for mTOR/p-mTOR and AKT/p-AKT with band densitometries; the total amount of
both AKT and mTOR increases over polydatin treatment; however, the ratio between phosphorylated and non-phosphorylated forms does not
change. b IF with ER-Tracker 24 h after polydatin treatment. ER Tracker stains the endoplasmic reticulum and its fluorescence is proportional to ER
swelling. c IF and flow cytometry for lysotracker on cells treated with polydatin (20 μM) and either IRE1 inhibitor 4μ8c or PERK inhibitor
GSK26064141. In the flow cytometry graphs, the medians of the fluorescence intensities are plotted. Both 4μ8c and GSK26064141 reduces the
effect of polydatin on autophagy. *p < 0.05, N = 3 (biological replicates); error bars = SEM
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the pharmacological synergism of the combination using
Chou-Talalay method [23]. The Viability assay (Fig. 5 a)
showed a significant difference between MCF7G6PD+ and
MCF7mock both at 24 h and 48 h after treatment. Inter-
estingly, lapatinib and polydatin had a synergic effect on
MCF7mock but no effect was observed on MCF7G6PD
+cells. These data were confirmed by apoptosis ana-
lysis with Annexin V/PI and assessed by flow cytome-
try (Fig. 5 c, d). In order to show that the synergic
effect was not limited to MCF7 cells line we per-
formed a similar experiment on MDA231 cells line
obtaining similar results (Fig. 5e).
Fig. 4 G6PD overexpression limits autophagy induction by Lapatinib. a IF and flow cytometry for LysoTracker on MCF7mock and MCF7G6PD+ after
polydatin (20 μM), lapatinib (20 μM) and their combination. Flow cytometry histograms show median fluorescence. G6PD+ modified cells were
not responsive to both polydatin and lapatinib. b IF and flow cytometry for LC3B on MCF7mock and MCF7G6PD+ after polydatin, lapatinib and their
combination. Flow cytometry histograms show median fluorescence. MCF7G6PD+ cells were not responsive to both polydatin and lapatinib. Both
IFs are example of three biological replicates that show similar results. c Immunoblot and band densitometry for LAMP1, p62, LC-3 on both
MCF7mock and MCF7G6PD+ treated with Lapatinib, polydatin and combinations of both drugs. *p < 0.05, N = 3 (biological replicates); error bars = SEM
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Autophagy mediates cell death and synergism
To determine if autophagy was responsible for cell death
and synergistic effect between polydatin and lapatinib, we
performed a study of synergism in presence of the autoph-
agy inhibitor 3-methyladenine (3-MA). This molecule
blocks autophagosome formation at earlier stages by inhi-
biting class III PI3K [36]. 3-MA (1 MM) concentration was
chosen accordingly to the literature [36–39]. When autoph-
agy is blocked the synergic effect seen by co-treating with
polydatin and lapatinib was lost (Fig. 6 a) resulting in a
Fig. 5 G6PD overexpression confers resistance to lapatinib while its inhibition potentiates its effect. a Viability assay on MCF7mock and MCF7G6PD+
treated with Lapatinib (20 μM) at 24 h and 48 h. IC50 induced by lapatinib at 24 h was 40 μM and 51 μM, respectively, while at 48 h 19.6 μM and
37.6 μM, respectively b Combination index plot from Compusyn software for the analysis of the synergism induced by the combination lapatinib/
polydatin. When the points are located below the threshold (1.0), it suggests that the drugs act synergistically. At both 24 and 48 h for the
beginning of the treatment, polydatin and lapatinib show a significant synergism. c Annexin V/PI flow cytometry analysis to determine apoptosis
in lapatinib and polydatin/lapatinib-treated cells. Drug combination is more effective on both MCF7mock and MCF7G6PD+ if compared to single
treatments. The effect on MCF7mock is markedly stronger. d Histograms of the results obtained in Annexin V/PI assay shown in C. e Combination
index plot from Compusyn software for the analysis of synergism of the combination lapatinib/polydatin on MDA-MB-231 cell line. The synergism
between polydatin and lapatinib is confirmed also on this cell line. * p < 0,05, N = 3 (biological replicates); error bar = SEM
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combination Index (CI) that was always higher than 1 (syn-
ergism is shown by a CI lower than 0.8. These data were
confirmed by apoptosis analysis (Fig. 6 b). In fact, lapatinib
caused an about 25% reduction of viability, its combination
with polydatin induced a 75% reduction, and when 3-MA
was added together with polydatin and lapatinib cell viabil-
ity was reduced of only 50%. 3-MA counteracted the effect
of lapatinib-polydatin combination, strongly suggesting that
the cytotoxic effect obtained by inhibiting G6PD and Lapa-
tinib was caused by increased autophagy.
G6PD expression is correlated to disease-free survival
(DFS) and recurrence in breast cancer patients
To identify the role and impact of G6PD in breast cancer
patients, an in silico analysis of two public available datasets
generated through the analysis of patient-derived material
was performed. The expression of G6PD across 5 breast
cancer subtypes (Her2+ enriched, Basal-like, Luminal A,
Luminal B and Normal-like), showed a statistically signifi-
cant higher expression of G6PD in Her2+ enriched tumour
material, compared to specimens derived from other breast
cancer subtypes (Fig. 7a+b). Furthermore, the comparison
of G6PD expression in patients with and without disease
recurrence, measured at the time of diagnosis, showed a
statistically significant higher expression of G6PD in
patients with future disease-recurrence when compared to
patients without future disease recurrence (Fig. 7c+d). The
significance of G6PD on disease-recurrence was further
supported through a Kaplan-Meier analysis of disease-free
survival (DFS) time against median expression of G6PD.
This analysis correlated an earlier disease-recurrence with
an increased expression of G6PD at the time of diagnosis
(Fig. 7e+f). The analysis of the METABRIC dataset has
shown that patients with a lower G6PD expression have a
3-year longer median DFS compared to patients with a
high G6PD expression (Fig. 7e). Similar trends were shown
for the Pawitan dataset (Fig. 7f), however both groups did
not cross the 50% survival mark.
Discussion
In this manuscript, we describe for the first time that
the inhibition of G6PD causes an activation of autopha-
gic flux, which synergistically increases the cytotoxic ef-
fect of Lapatinib on breast cancer cells. Pentose
phosphate pathway (PPP) is a major player in glucose
catabolism that results in the production of NADPH, ne-
cessary to control redox balance, lipid metabolism and
nucleotide precursors [6, 40]. G6PD is the limiting en-
zyme of the PPP and it is finely regulated following the
cell redox state and metabolic needs. PPP activity and
G6PD itself are often upregulated in cancer and are as-
sociated with aggressiveness, drug resistance and poor
prognosis [7–9]. Thus, inhibition of this pathway has
been pointed out as a major goal for the definition of
new cancer treatments [4]. Indeed, targeting G6PD re-
sults in cancer cytotoxicity, reduction of metastases and
restoration of sensitivity to drug [11, 12, 26, 35]. Never-
theless, the choice among G6PD inhibitors is very lim-
ited and debated [41]. Recently our group discovered
that the natural molecule polydatin directly inhibits
G6PD causing oxidative stress, endoplasmic reticulum
stress and apoptosis in cancer cells [26]. Polydatin is a
Fig. 6 Autophagy-mediated cell death. a Synergism between
polydatin and lapatinib in presence of 3-MA. All points are above
the threshold suggesting that 3-MA counteracts polydatin/lapatinib
effect and that autophagy is responsible for the synergism. b
Annexin V/PI assay after co-treatment with polydatin/lapatinib in the
presence of 3-MA. Viable cells change from 27.9% in polydatin/
lapatinib-treated cells to 50.7% in presence of 3-MA. Bar graph
summarizing the results of apoptosis analyses, statistical analysis
show a significant difference between lapatinib/polydatin and
lapatinib/polydatin/3-MA treatments. P < 0,05, N = 3; error
bar = Standard deviation
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glucoside of resveratrol that has been studied for many
years and for different pathological conditions, including
inflammation and cancer [42–44]. MCF7 is most widely
used breast cancer cell line for in vitro research [45].
PPP and G6PD have been proven to play an important
role in their metabolism [15, 46, 47] as well as they have
been used to study lapatinib effect and resistance espe-
cially in combination with other drugs [48, 49]. Here, we
show that, G6PD inhibition induced an increase of both
intracytoplasmic vesicles (puncta) that colocalize with
Lysotracker, a marker of acidic compartments, and
LC3B which is associated to autophagosomes. During
autophagy induction, LC3-I is converted into LC3-II
with a concurrent decrease in p62. LC3B activation was
confirmed also by immunoblotting.
In the study of autophagy flux, inhibition of lysosomal
degradation by chloroquine or bafilomycin A causes
accumulation of both LC3-II and p62, and this reflects
the amount of LC3-II and p62 that would have been de-
graded by autophagy over the treatment period [50–52].
Fig. 7 G6PD is inversely correlated to DFS in breast cancer patients. a, b Scatter plot presenting the normalized gene expression of G6PD within
breast cancer subtypes. Significance was tested comparing the expression in Her2+ population with other subtypes. Results highlight that the
expression of G6PD is significantly higher in the Her2+ population supporting the use of a G6PD inhibitor for this group of patients. c, d Scatter
plot representing the normalized gene expression of G6PD in patients with disease-free survival (DFS) and patients with disease recurrence.
Significant differences in the expression of G6PD is shown in the Metabric and Pawitan dataset. Both show a higher expression of G6PD in
patients with disease recurrence compared to patients without disease recurrence. Note: The analysis was performed using all sample population
based on the reduced numbers of Her2+ patients and the number of recurring and non-recurring patients within this selection. e, f Kaplan-Meier
analysis on DFS after a median split. Equal number of patients were in both groups. Significant differences in DFS are shown in the Metabric and
Pawitan dataset. Both show that an increased expression of G6PD results in an earlier time of relapse. Note: The difference in the graphs of
Metabric and Pawitan are based on the shorter length of follow-up of Pawitan compared to Metabric. The analysis was performed using all
sample population based on the reduced numbers of Her2+ patients and the number of recurring and non-recurring patients within
this selection
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In Fig. 2c the increase of p62 and LC3B in cells
co-treated with chloroquine is evident. Other studies
using metabolic inhibitor show an increase in autophagic
flux leading to cells death [53], this corroborate our
strategy to use metabolic autophagy inducer to potenti-
ate anticancer drug effect.
mTOR is a master regulator of cell metabolism by
controlling autophagy, among other processes. Typically,
when mTOR is inactive or inhibited, autophagy occurs.
Therefore, most of the molecules that influence autoph-
agy acts directly or indirectly on the mTOR pathway
[54]. Resveratrol, which can be produced from polydatin
degradation, has been described as mTOR inhibitor
[28, 55, 56]; thus, to exclude a direct effect of polydatin
on this pathway, we analysed the activation of mTOR
and its upstream regulator AKT. We showed that both
AKT and mTOR are not inhibited. A possible case in
which autophagy is induced independently from mTOR
is represented by the unfolded protein response process
that is initiated following ER stress [57, 58]. Indeed,
both IRE1 and PERK, which are the principal mediator
of UPR, have been described to induce autophagy inde-
pendently from mTOR status [39, 59]. Our results con-
firmed [26] that G6PD inhibition caused ER stress and
that, if UPR was inhibited by blocking IRE1 or PERK,
polydatin was not still able to induce autophagy.
Tyrosine kinase inhibitors are a class of drugs that are
largely used in clinical settings to treat different cancers
including breast carcinoma. The work of Gregory et al.
[22] pointed out that G6PD is responsible for resistance
to FMS-like tyrosine kinase 3 inhibitors in acute myeloid
leukaemia due to increased redox metabolism. Among
TKIs that are used to treat breast cancer, lapatinib has
been described to cause cancer cells cytotoxicity by in-
ducing autophagy [19, 34]. Therefore, we hypothesized
that G6PD might play a role in modulating lapatinib
effect on cancer cells. For this purpose, we created a cell
line overexpressing G6PD and showed that they are
resistant to autophagy induced by either lapatinib or
polydatin. On the other hand, cells that received the
mock plasmid showed a strong induction of autophagy,
especially with the combination of the two drugs. These
results were confirmed by viability analyses where the
MCF7G6PD+ were less sensitive to lapatinib. Moreover,
the analysis of synergism between polydatin and lapati-
nib showed that the two molecules were highly synergis-
tic in the MCF7mock at both 24 h and 48 h after
treatment, while this effect was less evident or absent on
the MCF7G6PD+. These results were confirmed by
Annexin V/PI analysis. Moreover, to confirm the role of
autophagy in cancer cell death, we analysed both syner-
gism and apoptosis in the presence of 3-metyladenin
(3-MA), which is a widely used autophagy inhibitor
[37, 60]. Differently from chloroquine and bafilomycin
A, 3-MA inhibits autophagosomes formation at early
stages. For these reasons, 3-MA has been widely used
in similar experiments [38, 60]. In these experimental
conditions, synergism was completely prevented and
cell viability increased from about 27% in polydatin/
lapatinib-treated cells to about 50% in the presence of
3-MA. In silico studies on two publicly available patient’s
databases showed a significant association between G6PD
and HER2+ patients and an inverse correlation between
G6PD expression and DFS. These data were on line with
other reports that used different databases [7, 8]. Possible
explanation of the synergistic mechanism showed here in-
volve autophagic cell death. Shimuzu et al. showed that
Bcl-2 family of protein, which is a regulator of apoptosis,
control autophagic cell death by binding to Beclin-1 and
APG5 [61]. Moreover, Ros induce JNK phosphorylation
can activate autophagy by interfering with the interaction
between Beclin-1 and bcl-2 [62]. In addition, another
mechanism that could be involved in this process is a
novel programmed autophagic cells death depend on iron
called ferroptosis. This involved an increase of lipid perox-
ides and excessive degradation of ferritin and NCOA4
[62, 63]. Future studies are necessary to understand
the precise role of this mechanisms and pathways in
the context described in this manuscript.
Conclusion
Taken together, our results led to the following conclu-
sions: i. G6PD blockade caused autophagy through ER
stress; ii. G6PD activity influenced lapatinib effect on
cancer cells by preventing autophagy; iii. G6PD inhibi-
tors such as polydatin might be used to increase lapati-
nib effect on breast cancer.
Cancer is more and more evidenced as a complex dis-
ease in which metabolic pathways play a fundamental
role, either for the growth, metastases or resistance to
treatments. It becomes evident that targeting these path-
ways is necessary to develop effective and resolute strat-
egies. Here we provide an example in which the
co-targeting of PPP and tyrosine kinase receptors lead to
synergistic effects on breast cancer cells. This approach
could be easily translated into clinical setting.
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